US 11292842
Anti-PD-1 antibodies for treatment of lung cancer
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11292842 (Anti-PD-1 antibodies for treatment of lung cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61K31/337